Japanese study on current Anticoagulation therapies for Patients with nonvalvular Atrial Fibrillation.

Not Applicable

• Conditions: nonvalvularAtrial Fibrillation patients

• Registration Number: JPRN-UMIN000009644
• Lead Sponsor: Kyoto University Graduate School of Medicine

Brief Summary

Patients with NVAF taking antithrombotics other than DTIs were enrolled in this cross-sectional study. Patient demographics and medication history were collected, and patients were classified as taking antiplatelet monotherapy (AP), anticoagulant monotherapy (AC), or combination therapy (AP+AC). OAC (AC and AP+AC) users were also stratified as naive (N; initiated within 6 months), switcher (S; switched within 6 months), or prevalent (P; continued over 6 months). A total of 3,053 patients (AP, 216; AC, 2,381; AP+AC, 456) from 268 sites were enrolled from 2012 to 2013. Significant differences were observed in CHADS2 (AP/AC/AP+AC: 2.0/2.1/2.7, P<0.0001), angina complications (20.1/8.6/32.1, P<0.0001), myocardial infarction (5.1/2.8/18.1, P<0.0001), prothrombin time-international normalized ratio (PT-INR) (-/2.00/1.94, P=0.0350) and others. There were 2,831 OAC users (N, 328; S, 213; P, 2,290). Significant differences were observed in history of bleeding (N/S/P: 2.4/9.4/4.5, P<0.001), PT-INR (1.83/2.01/2.00, P<0.0001) and others. In conclusion, patients taking an AP+AC had higher CHADS2 than those taking an AP or AC alone. Additionally, combination therapy (AP+AC) was preferred in patients with cardiovascular complications. ACs continued to be prescribed in patients with bleeding episodes, while APs were changed. Changes in AC regimens were not influenced by CHADS2 or complications, except history of bleeding.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-12-27
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 5000

Inclusion Criteria

Not provided

Exclusion Criteria

There are no exclusion criteria for this study.

Study & Design

• Study Type: Observational
• Study Design: Not specified